FDA Panel Recommends Approval Of Genzyme's Kynamro
A U.S. Food and Drug Administration advisory committee on Thursday recommended the agency approve Genzyme Corp.'s and Isis Pharmaceuticals Inc.'s cholesterol disorder treatment Kynamro, despite previous staff concerns about serious side...To view the full article, register now.
Already a subscriber? Click here to view full article